{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:13:33Z","timestamp":1774307613612,"version":"3.50.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>In Nigeria, low-dose prophylaxis is the standard of care as it reduces bleeding, development of target joints, arthropathy, and improvement of quality of life. Non-adherence or poor adherence can prevent the achievement of these outcomes. The levels and determinants of (non-)adherence among persons with haaemophilia (PWH) in Sub-Saharan Africa have not been evidenced. We aimed to evaluate self-reported adherence among PWH, provide evidence of determinants\/predictors of adherence, and establish the associations between nonadherence and presence of target joints and annualized bleed rate. A cross-sectional survey of 42 participants on low-dose prophylaxis recruited during outpatient appointments in 5 haemophilia treatment centers in Nigeria. We used the validated Haemophilia Regimen Treatment Adherence Scale- Prophylaxis (VERITAS -Pro), 24 questions on six subscales (time, dose, plan, remember, skip, and communicate) questionnaire. The options of VERITAS -Pro were represented in a 5 Likert scale and the possible subscale ranged from 4 points (most adherent) to 20 points (least adherent) and the possible total score ranged from 24 (most adherent) to 120 (least adherent) the cutoff for overall adherence put at &gt; 61 to indicate nonadherence. Information on the presence of target joints, the number of target joints, and annualized bleeding rates were collected from medical files. The mean age of the participants was 9.79 (6.29) years, with 96.6% having hemophilia A and 79.3% having target joints. Overall adherence to the prophylaxis regimen was 81.0%. The mean total VERITAS-Pro for the adherent group and the non-adherent group was 37.35 \u00b19.08 and 63.0\u00b1 6.37, respectively. The mean subscale scores for the adherent group ranged from 0.67 (communication) to 8.68 (planning), while the mean subscale scores range from 1.0 communication to 13.88 (planning) for the nonadherent group. The mean difference of all except the dosing subscale was statistically significant with p&lt;0.05. Only the skipping subscale showed a statistically significant positive correlation with ABR in the non-adherent group p = 0.02. The findings indicate that adherence was very good, and most were in communication with their treatment centers. The skipping subscale was significantly associated with ABR for the nonadherent group. Interventions aimed at improving adherence are the key to better treatment outcomes. A multicenter study was needed to assess the reason for poor adherence.<\/jats:p>","DOI":"10.1371\/journal.pone.0264600","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T13:49:22Z","timestamp":1675345762000},"page":"e0264600","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adherence to prophylaxis and bleeding outcome: A multicenter Nigerian study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-3195","authenticated-orcid":true,"given":"Theresa Ukamaka","family":"Nwagha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4505-8217","authenticated-orcid":true,"given":"Helen Chioma","family":"Okoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleh","family":"Yuguda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiana Enefiok","family":"Udo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutiat Kehinde","family":"Ogunfemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8082-352X","authenticated-orcid":true,"given":"Dalhat Haliru","family":"Gwarzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nnamdi Joel","family":"Osuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"pone.0264600.ref001","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1111\/hae.13272","article-title":"Low dose prophylaxis for children with haemophilia in a resource limited setting in south India\u2013a clinical audit report","volume":"23","author":"N Sidharian","year":"2017","journal-title":"Haemophilia"},{"key":"pone.0264600.ref002","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","article-title":"Haemophilia prophylaxis in young patients: a long-term follow-up","volume":"241","author":"T L\u00f6fqvist","year":"1997","journal-title":"J Intern Med"},{"key":"pone.0264600.ref003","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for haemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"J. Oldenburg","year":"2015","journal-title":"Blood"},{"key":"pone.0264600.ref004","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.","volume":"105","author":"J Astermark","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"pone.0264600.ref005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.","volume":"357","author":"MJ Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0264600.ref006","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/blood-2012-12-470898","article-title":"Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s","volume":"122","author":"K Fischer","year":"2013","journal-title":"Blood"},{"issue":"11","key":"pone.0264600.ref007","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"VS Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"5","key":"pone.0264600.ref008","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/jth.13298","article-title":"When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH","volume":"14","author":"K Fischer","year":"2016","journal-title":"J Thromb Haemost"},{"key":"pone.0264600.ref009","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have haemophilia A without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0264600.ref010","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in haemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0264600.ref011","doi-asserted-by":"crossref","first-page":"570","DOI":"10.25122\/jml-2022-0103","article-title":"Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with haemophilia","volume":"15","author":"A Batorova","year":"2022","journal-title":"J Med Life"},{"key":"pone.0264600.ref012","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bjh.17580","article-title":"Haemophilia: factoring in new therapies","volume":"194","author":"H Fassel","year":"2021","journal-title":"Br J Haematol"},{"key":"pone.0264600.ref013","first-page":"11","article-title":"Clinical audit of low dose prophylaxis program for Nigerian children with haemophilia","volume":"39","author":"TU Nwagha","year":"2022","journal-title":"West Afr J Med"},{"key":"pone.0264600.ref014","author":"VS Blanchette","journal-title":"Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders"},{"issue":"2","key":"pone.0264600.ref015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.14844","article-title":"Intracranial haemorrhage in children and adolescents with severe haemophilia A or B\u2014the impact of prophylactic treatment","volume":"179","author":"NG Andersson","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"pone.0264600.ref016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hae.13048","article-title":"Low dose prophylaxis in Tunisian children with haemophilia","volume":"23","author":"E Gouider","year":"2017","journal-title":"Haemophilia"},{"issue":"2","key":"pone.0264600.ref017","first-page":"247","article-title":"VERITAS-Pro: a new measure of adherence to prophylactic regimens in Haemophilia","volume":"16","author":"N Duncan","year":"2010"},{"key":"pone.0264600.ref018","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2012.01750.x","article-title":"Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life","volume":"88","author":"M Khawaji","year":"2012","journal-title":"Eur J Haematol"},{"key":"pone.0264600.ref019","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/hae.12136","article-title":"Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement t therapy","volume":"19","author":"W Mondorf","year":"2013","journal-title":"Haemophilia"},{"key":"pone.0264600.ref020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hae.12533","article-title":"Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey","volume":"21","author":"S Krishnan","year":"2015","journal-title":"Haemophilia"},{"issue":"5","key":"pone.0264600.ref021","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2516.2008.01843.x","article-title":"A survey of adherence to haemophilia therapy in six European countries: results and recommendations","volume":"14","author":"P De Moerloose","year":"2008","journal-title":"Haemophilia: the official journal of the World Federation of Hemophilia"},{"issue":"1","key":"pone.0264600.ref022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2516.2006.01192.x","article-title":"Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia","volume":"12","author":"K Lindvall","year":"2006","journal-title":"Haemophilia: the official journal of the World Federation of Hemophilia"},{"issue":"4","key":"pone.0264600.ref023","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2001.00534.x","article-title":"Barriers to compliance with prophylaxis therapy in haemophilia","volume":"7","author":"M Hacker","year":"2001","journal-title":"Haemophilia"},{"key":"pone.0264600.ref024","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/PPA.S126828","volume":"11","author":"R Cuesta-Barriuso","year":"2017","journal-title":"Patient Preference and Adherence"},{"key":"pone.0264600.ref025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/rth2.12301","article-title":"Haemophilia prophylaxis adherence and bleeding using a tailored frequency-escalated approach: the Candadian haemophilia primary prophylaxis study","volume":"4","author":"S Dover","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"pone.0264600.ref026","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3390\/healthcare9121702","article-title":"Medication adherence for haemophilia patients: outcome of prophylaxis treatment intervention","volume":"9","author":"FM Mokhtar","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"pone.0264600.ref027","article-title":"Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals","author":"LH Schrijvers","year":"2016","journal-title":"Haemophilia"},{"key":"pone.0264600.ref028","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in haemophilia","volume":"11","author":"CD Thomburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"pone.0264600.ref029","doi-asserted-by":"crossref","first-page":"e0169880","DOI":"10.1371\/journal.pone.0169880","article-title":"Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients","volume":"12","author":"SB van Os","year":"2017","journal-title":"PLoS ONE"},{"key":"pone.0264600.ref030","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/cts.12794","article-title":"Annual bleeding rates: pitfalls of clinical trial outcomes in haemophilia patients","volume":"13","author":"C Keipert","year":"2020","journal-title":"Clin Transl Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T22:37:14Z","timestamp":1701815834000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264600"}},"subtitle":[],"editor":[{"given":"Jos\u00e9 Luiz Fernandes","family":"Vieira","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0264600","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.14.22270964","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}